Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales totaling 9,500 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and the subsequent sale of common stock.
• A total of 9,500 stock options were exercised at a price of $146.03 per share.
• The resulting 9,500 shares of common stock were sold at a weighted average price of $562.00 to $577.82, depending on the specific transaction.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 41,153 shares of common stock directly, with additional holdings through a spouse, trusts, and other indirect ownerships.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by a CEO can be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-determined and structured approach to stock sales, which can mitigate insider trading concerns.
• The exercise price of the stock options ($146.03) is significantly lower than the sale prices, indicating a profitable transaction for the reporting person.

Negatives

• A significant number of shares (9,500) were sold by a key executive, which could be perceived negatively by the market, despite being part of a pre-planned strategy.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon the exercise of all remaining options under the plan, introducing a time-bound element to future transactions.
• The plan is tied to the exercise of stock options that expire on March 17, 2027, creating a potential need for further transactions or forfeiture of options.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until all 1,734,410 stock options under the plan are exercised, whichever occurs first. The options expire on March 17, 2027.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The plan will continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a CEO like Martine Rothblatt is a common strategy to diversify holdings or manage personal finances while adhering to insider trading regulations. The significant difference between the option exercise price and the sale price suggests a profitable outcome for the executive, reflecting the company's stock performance.

Stakeholder Impact

• Shareholders may interpret the sale of shares by the CEO, even under a 10b5-1 plan, as a signal of reduced confidence or a need for liquidity, potentially impacting share price sentiment.
• Employees holding stock options may view the CEO's profitable exercise and sale as an indicator of the company's financial health and stock value.

Next Steps

• Continuation of the 10b5-1 trading plan until its termination conditions are met.
• Potential further transactions under the plan until December 31, 2026, or exercise of all options.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine Rothblatt, Stock Options, Insider Trading, 10b5-1 Plan, Common Stock, Beneficial Ownership, Executive Transactions